VC: Raven biotechnologies leads with $48.3M fourth round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Raven biotechnologies
South San Francisco

$48.3 million
Fourth round

Vulcan Capital

The money goes to the clinical development program for RAV12 for gastrointestinal cancers as well as pre-clinical work for a second product candidate.

Alinea Pharmaceuticals
Cambridge, MA

$45 million
first round

MPM Capital

Alinea is developing a treatment for diabetic neuropathy.

Light Sciences Oncology
Seattle

$35 million
first round

Essex Woodlands Health Ventures

The company is developing Light Infusion Technology for the treatment of solid tumors.

VIRxSYS
Gaithersburg, MD

$31 million
fifth round

undisclosed

Earlier closings of this round were used to complete a Phase I clinical trial for the VRX496 gene-based anti-HIV immunotherapy; the remainder of the funds will be used for their Phase II trial and to continue to advance its lentiviral vector platform technology.

Cadence Pharmaceuticals
San Diego

$25 million
first round

Domain Associates

Cadence is focused on the development and commercialization of therapeutics used primarily in the hospital setting.

Aerie Pharmaceuticals
Research Triangle Park, NC

$21 million
first round

Alta Partners, Texas Pacific Group Ventures

The company's initial drug discovery and development efforts are focused on creating a pipeline of products for glaucoma.

Verax Biomedical
Worcester, MA

$15 million
second round

KB Partners

The money will be used to complete development and begin commercialization of its first product, the Platelet PGD test.

GlycoFi
Lebanon, NH

$11 million
round three extension

Polaris Venture Partners

GlycoFi has been developing technology for the creation and efficient production of Next Generation Biotherapeutics.

Agendia
Amsterdam

Undisclosed
second round

Van Herk Group

Agendia commercializes microarray-based diagnostics.